Monoclonal antibodies against PCSK9

Drug / Medication

Antibodies developed by the pharmaceutical industry to inhibit PCSK9, leading to significant LDL reduction and cardiovascular event reduction.

Mentioned in 1 video

Videos Mentioning Monoclonal antibodies against PCSK9

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

Peter Attia MD

Antibodies developed by the pharmaceutical industry to inhibit PCSK9, leading to significant LDL reduction and cardiovascular event reduction.